Lotte Biologics
Pharmaceutical Manufacturing • 
300, Olympic-ro, Korea, Republic of • 501-1000 Employees
Company overview
| Headquarters | 300, Olympic-ro, Korea, Republic of |
| Phone number | +82232138250 |
| Websites | |
| NAICS | 3254 |
| Founded | 2022 |
| Employees | 501-1000 |
| Socials |
Key Contacts at Lotte Biologics
Richard Lee
Chairman And Chief Executive Officer
James Park
President And Chief Executive Officer
Tim Dwyer
Associate Director, Security
Steve Lee
Senior Director Finance
Younghwan Paik
Lotte Biologics, Technical Operations Team Lead, Director
Angela Au
Associate Director, Manufacturing Technology
John Oh
Director Of Business Development And Sales
Eric Labarge
Director, Environmental, Occupational Health, Safety, Security, And Sustainability
Hannah Oh
Global Bd Director
Diana Brown
Director Of Business Development And Sales
Lotte Biologics Email Formats
Lotte Biologics uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@lottebiologics.com), used 43.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@lottebiologics.com | 61.4% |
{first initial}.{last name} | j.doe@lottebiologics.com | 34.7% |
{2char} | {2char}@lotte.net | 2.2% |
About Lotte Biologics
Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to deliver therapies that contribute to a healthier world. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. The facility offers a total production capacity of 40,000L, supported by eight 5,000L stainless steel bioreactors. Additionally, the campus includes extensive analytical QC testing laboratories and warehouse facilities that have received over 62 regulatory approvals from agencies worldwide. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) services. With over $100 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, along with multiple 3,000L bioreactors to meet clinical production needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity. Through our commitment to delivering innovative medicines to patients worldwide, LOTTE BIOLOGICS aims to become a top-tier global CDMO company in the biopharmaceutical industry.
Lotte Biologics revenue & valuation
| Annual revenue | $46,100,000 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $147,300,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 501-1000
Seniority
Employees
Employees by Department
Lotte Biologics has 208 employees across 13 departments.
Departments
Number of employees
Funding Data
Lotte Biologics has never raised funding before.
Lotte Biologics Tech Stack
Discover the technologies and tools that power Lotte Biologics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript frameworks
Tag managers
Programming languages
Webmail
Reverse proxies
JavaScript frameworks
Miscellaneous
Security
SSL/TLS certificate authorities
JavaScript libraries
Analytics
United Kingdom
France
Frequently asked questions
4.8
40,000 users
